AR006305A1 - Un compuesto de bencilaminopiperidina sustituido, su uso y una composicion farmaceutica que lo contiene - Google Patents
Un compuesto de bencilaminopiperidina sustituido, su uso y una composicion farmaceutica que lo contieneInfo
- Publication number
- AR006305A1 AR006305A1 ARP960104045A AR10404596A AR006305A1 AR 006305 A1 AR006305 A1 AR 006305A1 AR P960104045 A ARP960104045 A AR P960104045A AR 10404596 A AR10404596 A AR 10404596A AR 006305 A1 AR006305 A1 AR 006305A1
- Authority
- AR
- Argentina
- Prior art keywords
- halo
- alkoxy
- haloalkyl
- substituted
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 241000590002 Helicobacter pylori Species 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010042496 Sunburn Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- -1 benzylaminopiperidine compound Chemical class 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 1
- 125000000262 haloalkenyl group Chemical group 0.000 abstract 1
- 125000000232 haloalkynyl group Chemical group 0.000 abstract 1
- 229940037467 helicobacter pylori Drugs 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto de bencilaminopiperidina sustituida de fórmula (I), y sus sales farmacéuticamente aceptables, en la que: R es haloalquilo C1-8,haloalquenilo C2-8, haloalquinilo C2-8 o haloalquilo C1-8 sustituido con hidroxi o alcoxi C1-8 yR 1 es hidrógeno, halo o alcoxi C1-6 o R y R1, juntocon los dos átomos de carbono compartidos entre el anillo bencénico y R y R1, completan un grupo cicloalquilo C4-6 condensado en el que un átomo de carbonoestá opcionalmente reemplazado poroxígeno y en el que uno o dos de los átomos de carbono están opcionalmente sustituidos con hasta cinco sustituyentesseleccionados entre halo, alquilo C1-6 y haloalquilo C1-6; X es alcoxi C1-6, haloalcoxi C1-6, fenoxi o halo y Ar es feniloopcional mente sustituidocon halo. Estos compuestos son útiles en el tratamiento de un trastorno gastrointestinal, un trastorno del sistema nervioso central (SNC), unaenfermedad inflamatoria, emesis, incontinencia urinaria, dolor, migrana,quem aduras solares, enfermedades, trastornos y afecciones adversas causadaspor Helicobacter pylori o angiogénesis, especialmente trastornos del SNC, en mamíferos, especialmente seres humanos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB9500683 | 1995-08-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR006305A1 true AR006305A1 (es) | 1999-08-25 |
Family
ID=11004362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960104045A AR006305A1 (es) | 1995-08-24 | 1996-08-20 | Un compuesto de bencilaminopiperidina sustituido, su uso y una composicion farmaceutica que lo contiene |
Country Status (42)
| Country | Link |
|---|---|
| US (1) | US6506775B1 (es) |
| EP (2) | EP0861235B1 (es) |
| JP (1) | JP3084069B2 (es) |
| KR (1) | KR100288673B1 (es) |
| CN (1) | CN1153764C (es) |
| AP (1) | AP643A (es) |
| AR (1) | AR006305A1 (es) |
| AT (2) | ATE208377T1 (es) |
| AU (1) | AU702698B2 (es) |
| BG (1) | BG64126B1 (es) |
| BR (1) | BR9609989A (es) |
| CA (1) | CA2227814C (es) |
| CO (1) | CO4480738A1 (es) |
| CZ (1) | CZ297543B6 (es) |
| DE (2) | DE69631390T2 (es) |
| DK (2) | DK1114817T3 (es) |
| DZ (1) | DZ2086A1 (es) |
| ES (2) | ES2211684T3 (es) |
| HK (1) | HK1014935A1 (es) |
| HR (1) | HRP960386B1 (es) |
| HU (1) | HU225480B1 (es) |
| IL (1) | IL119078A (es) |
| IS (1) | IS1947B (es) |
| MA (1) | MA23961A1 (es) |
| MX (1) | MX9801467A (es) |
| MY (1) | MY114800A (es) |
| NO (1) | NO310720B1 (es) |
| NZ (1) | NZ308207A (es) |
| OA (1) | OA10666A (es) |
| PE (2) | PE20010700A1 (es) |
| PL (1) | PL186773B1 (es) |
| PT (2) | PT861235E (es) |
| RO (1) | RO119299B1 (es) |
| RU (1) | RU2152930C2 (es) |
| SI (2) | SI0861235T1 (es) |
| SK (1) | SK282925B6 (es) |
| TN (1) | TNSN96107A1 (es) |
| TR (1) | TR199800300T1 (es) |
| TW (1) | TW340842B (es) |
| UA (1) | UA48981C2 (es) |
| WO (1) | WO1997008144A1 (es) |
| YU (1) | YU49122B (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9706196A (es) * | 1996-08-14 | 1998-02-28 | Pfizer | Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p. |
| TW426667B (en) * | 1997-11-19 | 2001-03-21 | Pfizer | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists |
| US6777428B1 (en) | 1999-02-10 | 2004-08-17 | Eli Lilly And Company | 5-HT1f agonist |
| EP1175417B1 (en) * | 1999-05-06 | 2004-01-07 | Pfizer Products Inc. | Substituted benzolactam compounds |
| RS49964B (sr) | 1999-05-17 | 2008-09-29 | Pfizer Products Inc., | Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli |
| WO2000071538A2 (en) * | 1999-05-21 | 2000-11-30 | Pfizer Products Inc. | 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
| JP2001172178A (ja) * | 1999-10-25 | 2001-06-26 | Pfizer Prod Inc | 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン |
| US20020049211A1 (en) * | 2000-09-06 | 2002-04-25 | Sobolov-Jaynes Susan Beth | Combination treatment for depression and anxiety |
| EP1192952A3 (en) * | 2000-09-28 | 2003-03-26 | Pfizer Products Inc. | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist |
| US6911544B2 (en) | 2002-10-23 | 2005-06-28 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine |
| WO2004094380A1 (en) | 2003-04-18 | 2004-11-04 | Eli Lilly And Company | (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists |
| CA2566920A1 (en) * | 2004-05-21 | 2005-12-01 | Pfizer Products Inc. | Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine |
| US7541357B2 (en) | 2004-07-15 | 2009-06-02 | Amr Technology, Inc. | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
| GEP20125566B (en) | 2005-07-15 | 2012-07-10 | Amr Technology Inc | Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| CA2664113C (en) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| JP4611444B2 (ja) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール |
| CA2682727C (en) | 2007-04-02 | 2016-03-22 | Banyu Pharmaceutical Co., Ltd. | Indoledione derivative |
| EP3103791B1 (en) | 2007-06-27 | 2018-01-31 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| US8598184B2 (en) | 2008-03-03 | 2013-12-03 | Tiger Pharmatech | Protein kinase inhibitors |
| US7951822B2 (en) | 2008-03-31 | 2011-05-31 | Kowa Company, Ltd. | 1,3-dihydroisobenzofuran derivatives |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| PE20120373A1 (es) | 2009-05-12 | 2012-05-17 | Albany Molecular Res Inc | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina |
| WO2010132487A1 (en) | 2009-05-12 | 2010-11-18 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
| CN102458123A (zh) | 2009-05-12 | 2012-05-16 | 阿尔巴尼分子研究公司 | 芳基、杂芳基和杂环取代的四氢异喹啉及其用途 |
| JP5099731B1 (ja) | 2009-10-14 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | ｐ５３活性を増大する置換ピペリジン及びその使用 |
| EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| US8518907B2 (en) | 2010-08-02 | 2013-08-27 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
| DK2606134T3 (da) | 2010-08-17 | 2019-07-22 | Sirna Therapeutics Inc | RNA-Interferens-formidlet inhibering af hepatitis-B-virus (HBV)-genekspression ved hjælp af kort interfererende nukleinsyre (siNA) |
| EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
| EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| US20140045847A1 (en) | 2011-04-21 | 2014-02-13 | Piramal Enterprises Limited | Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP3358013B1 (en) | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| RU2660429C2 (ru) | 2012-09-28 | 2018-07-06 | Мерк Шарп И Доум Корп. | Новые соединения, которые являются ингибиторами erk |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神***病を処置するための方法および組成物 |
| AU2013352568B2 (en) | 2012-11-28 | 2019-09-19 | Merck Sharp & Dohme Llc | Compositions and methods for treating cancer |
| ES2707305T3 (es) | 2012-12-20 | 2019-04-03 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de HDM2 |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3706742B1 (en) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5232929A (en) * | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
| US5364943A (en) * | 1991-11-27 | 1994-11-15 | Pfizer Inc. | Preparation of substituted piperidines |
| CZ293955B6 (cs) * | 1991-03-26 | 2004-08-18 | Pfizeráinc | Postup přípravy substituovaných piperidinů |
| DE69213451T2 (de) * | 1991-06-20 | 1997-01-09 | Pfizer | Fluoralkoxybenzylaminoderivate stickstoffhaltiger heterocyclen |
| US5340826A (en) * | 1993-02-04 | 1994-08-23 | Pfizer Inc. | Pharmaceutical agents for treatment of urinary incontinence |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| EP0653208A3 (en) * | 1993-11-17 | 1995-10-11 | Pfizer | Substance P antagonists for the treatment or prevention of sunburn. |
| EP0655246A1 (en) * | 1993-11-30 | 1995-05-31 | Pfizer Inc. | Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria |
| DE69623580T2 (de) * | 1995-12-21 | 2003-01-09 | Pfizer | 3-((5-Substituierte Benzyl)Amino)-2-Phenylpiperidine als Substance-P-Antagonisten |
| US5990125A (en) | 1996-01-19 | 1999-11-23 | Pfizer Inc. | NK-1 receptor antagonists for the treatment of cancer |
-
1996
- 1996-06-04 TW TW085106675A patent/TW340842B/zh active
- 1996-06-10 AT AT96914375T patent/ATE208377T1/de not_active IP Right Cessation
- 1996-06-10 DK DK01108350T patent/DK1114817T3/da active
- 1996-06-10 JP JP09510015A patent/JP3084069B2/ja not_active Expired - Fee Related
- 1996-06-10 TN TNTNSN96107A patent/TNSN96107A1/fr unknown
- 1996-06-10 DE DE69631390T patent/DE69631390T2/de not_active Expired - Fee Related
- 1996-06-10 RO RO98-00334A patent/RO119299B1/ro unknown
- 1996-06-10 ES ES01108350T patent/ES2211684T3/es not_active Expired - Lifetime
- 1996-06-10 CA CA002227814A patent/CA2227814C/en not_active Expired - Fee Related
- 1996-06-10 ES ES96914375T patent/ES2163017T3/es not_active Expired - Lifetime
- 1996-06-10 SI SI9630374T patent/SI0861235T1/xx unknown
- 1996-06-10 PL PL96325332A patent/PL186773B1/pl not_active IP Right Cessation
- 1996-06-10 SI SI9630670T patent/SI1114817T1/xx unknown
- 1996-06-10 EP EP96914375A patent/EP0861235B1/en not_active Expired - Lifetime
- 1996-06-10 PT PT96914375T patent/PT861235E/pt unknown
- 1996-06-10 DK DK96914375T patent/DK0861235T3/da active
- 1996-06-10 AT AT01108350T patent/ATE258166T1/de not_active IP Right Cessation
- 1996-06-10 BR BR9609989A patent/BR9609989A/pt not_active Application Discontinuation
- 1996-06-10 CN CNB961965037A patent/CN1153764C/zh not_active Expired - Fee Related
- 1996-06-10 PT PT01108350T patent/PT1114817E/pt unknown
- 1996-06-10 WO PCT/IB1996/000572 patent/WO1997008144A1/en active IP Right Grant
- 1996-06-10 UA UA98020924A patent/UA48981C2/uk unknown
- 1996-06-10 RU RU98102959/04A patent/RU2152930C2/ru not_active IP Right Cessation
- 1996-06-10 AU AU57769/96A patent/AU702698B2/en not_active Ceased
- 1996-06-10 MX MX9801467A patent/MX9801467A/es active IP Right Grant
- 1996-06-10 CZ CZ0052198A patent/CZ297543B6/cs not_active IP Right Cessation
- 1996-06-10 HU HU9901159A patent/HU225480B1/hu not_active IP Right Cessation
- 1996-06-10 TR TR1998/00300T patent/TR199800300T1/xx unknown
- 1996-06-10 DE DE69616817T patent/DE69616817T2/de not_active Expired - Fee Related
- 1996-06-10 EP EP01108350A patent/EP1114817B1/en not_active Expired - Lifetime
- 1996-06-10 KR KR1019980701310A patent/KR100288673B1/ko not_active IP Right Cessation
- 1996-06-10 SK SK207-98A patent/SK282925B6/sk not_active IP Right Cessation
- 1996-06-10 NZ NZ308207A patent/NZ308207A/en unknown
- 1996-08-15 IL IL11907896A patent/IL119078A/xx not_active IP Right Cessation
- 1996-08-20 AR ARP960104045A patent/AR006305A1/es active IP Right Grant
- 1996-08-21 PE PE2001000276A patent/PE20010700A1/es not_active Application Discontinuation
- 1996-08-21 DZ DZ960130A patent/DZ2086A1/fr active
- 1996-08-21 PE PE1996000625A patent/PE1398A1/es not_active Application Discontinuation
- 1996-08-22 HR HR960386A patent/HRP960386B1/xx not_active IP Right Cessation
- 1996-08-23 MA MA24339A patent/MA23961A1/fr unknown
- 1996-08-23 YU YU47896A patent/YU49122B/sh unknown
- 1996-08-23 MY MYPI96003496A patent/MY114800A/en unknown
- 1996-08-24 AP APAP/P/1996/000850A patent/AP643A/en active
- 1996-08-26 CO CO96045248A patent/CO4480738A1/es unknown
-
1997
- 1997-12-30 IS IS4644A patent/IS1947B/is unknown
-
1998
- 1998-02-23 OA OA9800023A patent/OA10666A/en unknown
- 1998-02-23 NO NO19980751A patent/NO310720B1/no unknown
- 1998-02-27 BG BG102288A patent/BG64126B1/bg unknown
- 1998-12-30 HK HK98119203A patent/HK1014935A1/xx not_active IP Right Cessation
-
2000
- 2000-05-01 US US09/564,398 patent/US6506775B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR006305A1 (es) | Un compuesto de bencilaminopiperidina sustituido, su uso y una composicion farmaceutica que lo contiene | |
| AR016523A1 (es) | Compuestos de indol como agentes anti-inflamatorios/analgesicos, composiciones farmaceuticas que los contienen y procedimiento de tratamiento | |
| AU550774B2 (en) | 1-aryl-2-aminomethyl cyclopropane carboxylates | |
| NO883587L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive indolderivater. | |
| AR008377A1 (es) | Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto | |
| AR016422A1 (es) | Compuestos de esteres ciclicos de piperidinilaminometil trifluorometilo como antagonista de la sustancia p; composiciones farmaceuticas y procedimientos detratamiento. | |
| ATE129696T1 (de) | 8-substituierte-2-aminotetraline. | |
| MX9204858A (es) | Mejoras en derivados de 2-(piperazinoalquil)indol condensados en posiciones 1,7, asi como un procedimiento y productos intermedios para su preparacion y medicamentos que contienen estos compuestos. | |
| SE8404308L (sv) | Polyprenylkarboxylsyraamider, forfarande for deras framstellning samt farmaceutiska kompositioner innehallande dessa foreningar | |
| ZA964842B (en) | Indole indazole and benzisoxazole compounds their process of preparation and the pharmaceutical compositions which contain them | |
| AU8143487A (en) | New derivatives of 2,2-dimethyl cyclopropane carboxylic acid having a saturated halogenated chain in position 3, the process and the intermediates for their preparation, their use as pesticides and the compositions containing them | |
| FI853685A0 (fi) | Nya n-alk(en)yl-n-(o,o-disubstituerade -tiofosforyl)-n'n'-disubstituerade glycinamider, foerfarande foer framstaellning av dessa samt kvalstergifter, insektgifter och svampgifter vilka innehaoller dessa som aktiv bestaondsdel. | |
| FI910159A0 (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 9a-hydroxi-3-oxo-4,24(25)-stigmastadien-26 -syraderivat. | |
| DK0989112T3 (da) | Mellemprodukter til fremstilling af guanidinomethylcyclohexancarboxylsyreesterderivater | |
| DK0824100T3 (da) | Tricykliske piperidinylaminoforbindelser som substans P-antagonister | |
| ECSP982736A (es) | Compuestos de eteres ciclicos de piperidinilaminometil trifluorometilo como antagonistas de la sustancia p. | |
| FR2021123A1 (fr) | Nouveaux derives du 1,3-diamino-propane-2-ol | |
| SE8401064L (sv) | Nya isoxazoler och forfarande for framstellning derav | |
| DK69281A (da) | Fremgangsmaade til fremstilling af salte af alkancarboxylsyrer samt til fremstilling af topisk anvendelige farmaceutiske praeparater indeholdende disse salte |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |